David A. Hollander, MD, MBA
David A. Hollander, MD, MBA joined Aerie Pharmaceuticals in November 2019 as Chief Research and Development Officer, where he directs preclinical and clinical research, clinical development as well as medical and professional affairs. Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, and earned his medical degree at the University of Pennsylvania School of Medicine. He obtained an M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania. Dr. Hollander completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease and Refractive Surgery at the Jules Stein Eye Institute/University of California, Los Angeles.
Upon completing his fellowship, Dr. Hollander joined the faculty of the Cornea and Uveitis Division at Jules Stein and served as the Assistant Chief of Ophthalmology at the Greater Los Angeles Veterans Affairs Medical Center. Dr. Hollander began his career in industry in 2006 at Allergan as a Medical Director of Ophthalmology. Over the next decade at Allergan, Dr. Hollander held a number of leadership roles including Vice President of Eye Care for US Medical Affairs, VP and Head of Eye Care for Global Medical Affairs, as well as Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. During this time, Dr. Hollander continued to see patients and instruct residents and fellows in cataract surgery and corneal transplantation. In 2010, the residents at the Jules Stein Eye Institute awarded him with the faculty teaching award.
In 2016, Dr. Hollander joined Ora, Inc, the leading ophthalmic CRO, as Chief Medical Officer. While at Ora, Dr. Hollander oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints, most notably the development of novel mobility courses for evaluating treatments for inherited retinal diseases.
Dr. Hollander has authored more than 75 papers in the peer-reviewed literature and multiple books chapters and holds multiple patents. He is also a reviewer for numerous journals focusing on ophthalmology, current eye research, and managed care. He has lectured nationally and internationally on topics ranging from endpoint selection, genetics, ocular surface disease, innovative treatments in eye care, and collaborations between academic universities and industry.